5 | logarithm of the concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50) | FHH/EurMcwi | female | -8.295 | | phenylephrine (1 umol/l) (for 0.2 hours) then sodium nitroprusside (0~3 umol/l) and drug dose time series (for 1 hours) | 55496 | phenylephrine (1 umol/l) (for 0.2 hours) | | sodium nitroprusside (0~3 umol/l) | drug dose time series (for 1 hours) | | | | | |

5 | logarithm of the concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50) | FHH/EurMcwi | male | -8.0199 | | phenylephrine (1 umol/l) (for 0.2 hours) then sodium nitroprusside (0~3 umol/l) and drug dose time series (for 1 hours) | 55499 | phenylephrine (1 umol/l) (for 0.2 hours) | | sodium nitroprusside (0~3 umol/l) | drug dose time series (for 1 hours) | | | | | |

6 | logarithm of the concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50) | FHH/EurMcwi | female | -8.2912 | | controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) (for 0.2 hours) then sodium nitroprusside (0~3 umol/l) and drug dose time series (for 1 hours) | 55485 | controlled sodium content diet (4 %) (for 21 days) | | phenylephrine (1 umol/l) (for 0.2 hours) | | sodium nitroprusside (0~3 umol/l) | drug dose time series (for 1 hours) | | | |

6 | logarithm of the concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50) | FHH/EurMcwi | male | -8.6692 | | controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) (for 0.2 hours) then sodium nitroprusside (0~3 umol/l) and drug dose time series (for 1 hours) | 55491 | controlled sodium content diet (4 %) (for 21 days) | | phenylephrine (1 umol/l) (for 0.2 hours) | | sodium nitroprusside (0~3 umol/l) | drug dose time series (for 1 hours) | | | |

2 | logarithm of the concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50) | FHH/EurMcwi | male | -8.5925 | | phenylephrine (1 umol/l) (for 0.2 hours) then sodium nitroprusside (0~3 umol/l) and drug dose time series (for 1 hours) | 54619 | phenylephrine (1 umol/l) (for 0.2 hours) | | sodium nitroprusside (0~3 umol/l) | drug dose time series (for 1 hours) | | | | | |

5 | logarithm of the concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50) | FHH/EurMcwi | female | -8.5086 | | controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) (for 0.2 hours) then sodium nitroprusside (0~3 umol/l) and drug dose time series (for 1 hours) | 56016 | controlled sodium content diet (4 %) (for 21 days) | | phenylephrine (1 umol/l) (for 0.2 hours) | | sodium nitroprusside (0~3 umol/l) | drug dose time series (for 1 hours) | | | |

11 | logarithm of the concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50) | FHH/EurMcwi | male | -8.2075 | | controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) (for 0.2 hours) then sodium nitroprusside (0~3 umol/l) and drug dose time series (for 1 hours) | 56028 | controlled sodium content diet (4 %) (for 21 days) | | phenylephrine (1 umol/l) (for 0.2 hours) | | sodium nitroprusside (0~3 umol/l) | drug dose time series (for 1 hours) | | | |

6 | logarithm of the concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50) | FHH/EurMcwi | female | -8.5517 | | phenylephrine (1 umol/l) (for 0.2 hours) then sodium nitroprusside (0~3 umol/l) and drug dose time series (for 1 hours) | 56000 | phenylephrine (1 umol/l) (for 0.2 hours) | | sodium nitroprusside (0~3 umol/l) | drug dose time series (for 1 hours) | | | | | |

5 | logarithm of the concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50) | FHH/EurMcwi | male | -8.9184 | | phenylephrine (1 umol/l) (for 0.2 hours) then sodium nitroprusside (0~3 umol/l) and drug dose time series (for 1 hours) | 56006 | phenylephrine (1 umol/l) (for 0.2 hours) | | sodium nitroprusside (0~3 umol/l) | drug dose time series (for 1 hours) | | | | | |

6 | maximum contractile force per wet weight of aorta | FHH/EurMcwi | female | 1.9017 | g/mg | controlled sodium content diet (4 %) (for 14 days) then potassium ion (80 mmol/l) (for 0.2 hours) and phenylephrine (10 umol/l) (for 0.2 hours) | 63166 | controlled sodium content diet (4 %) (for 14 days) | | potassium ion (80 mmol/l) (for 0.2 hours) | phenylephrine (10 umol/l) (for 0.2 hours) | | | | | |

117 | maximum contractile force per wet weight of aorta | FHH/EurMcwi | male | 1.3081 | g/mg | controlled sodium content diet (4 %) (for 14 days) then potassium ion (80 mmol/l) (for 0.2 hours) and phenylephrine (10 umol/l) (for 0.2 hours) | 63177 | controlled sodium content diet (4 %) (for 14 days) | | potassium ion (80 mmol/l) (for 0.2 hours) | phenylephrine (10 umol/l) (for 0.2 hours) | | | | | |

10 | maximum contractile force per wet weight of aorta | FHH/EurMcwi | female | 1.76 | g/mg | controlled sodium content diet (4 %) (for 21 days) then potassium ion (80 mmol/l) (for 0.2 hours) and phenylephrine (10 umol/l) (for 0.2 hours) | 57348 | controlled sodium content diet (4 %) (for 21 days) | | potassium ion (80 mmol/l) (for 0.2 hours) | phenylephrine (10 umol/l) (for 0.2 hours) | | | | | |

55 | maximum contractile force per wet weight of aorta | FHH/EurMcwi | male | 1.0305 | g/mg | controlled sodium content diet (4 %) (for 21 days) then potassium ion (80 mmol/l) (for 0.2 hours) and phenylephrine (10 umol/l) (for 0.2 hours) | 57367 | controlled sodium content diet (4 %) (for 21 days) | | potassium ion (80 mmol/l) (for 0.2 hours) | phenylephrine (10 umol/l) (for 0.2 hours) | | | | | |

10 | maximum contractile force per wet weight of aorta | FHH/EurMcwi | female | 1.23 | g/mg | controlled sodium content diet (4 %) (for 21 days) then potassium ion (80 mmol/l) (for 0.2 hours) and phenylephrine (10 umol/l) (for 0.2 hours) | 56984 | controlled sodium content diet (4 %) (for 21 days) | | potassium ion (80 mmol/l) (for 0.2 hours) | phenylephrine (10 umol/l) (for 0.2 hours) | | | | | |

10 | maximum contractile force per wet weight of aorta | FHH/EurMcwi | male | 1.361 | g/mg | controlled sodium content diet (4 %) (for 21 days) then potassium ion (80 mmol/l) (for 0.2 hours) and phenylephrine (10 umol/l) (for 0.2 hours) | 56990 | controlled sodium content diet (4 %) (for 21 days) | | potassium ion (80 mmol/l) (for 0.2 hours) | phenylephrine (10 umol/l) (for 0.2 hours) | | | | | |

49 | maximum contractile force per wet weight of aorta | FHH/EurMcwi | male | 1.0806 | g/mg | potassium ion (80 mmol/l) (for 0.2 hours) and phenylephrine (10 umol/l) (for 0.2 hours) | 55821 | potassium ion (80 mmol/l) (for 0.2 hours) | phenylephrine (10 umol/l) (for 0.2 hours) | | | | | | | |

9 | maximum contractile force per wet weight of aorta | FHH/EurMcwi | female | 1.51 | g/mg | potassium ion (80 mmol/l) (for 0.2 hours) and phenylephrine (10 umol/l) (for 0.2 hours) | 55802 | potassium ion (80 mmol/l) (for 0.2 hours) | phenylephrine (10 umol/l) (for 0.2 hours) | | | | | | | |

5 | maximum contractile force per wet weight of aorta | FHH/EurMcwi | female | 1.942 | g/mg | potassium ion (80 mmol/l) (for 0.2 hours) and phenylephrine (10 umol/l) (for 0.2 hours) | 55010 | potassium ion (80 mmol/l) (for 0.2 hours) | phenylephrine (10 umol/l) (for 0.2 hours) | | | | | | | |

5 | maximum contractile force per wet weight of aorta | FHH/EurMcwi | male | 1.726 | g/mg | potassium ion (80 mmol/l) (for 0.2 hours) and phenylephrine (10 umol/l) (for 0.2 hours) | 55013 | potassium ion (80 mmol/l) (for 0.2 hours) | phenylephrine (10 umol/l) (for 0.2 hours) | | | | | | | |

12 | maximum contractile force per wet weight of aorta | FHH/EurMcwi | female | 1.5617 | g/mg | potassium ion (80 mmol/l) (for 0.2 hours) and phenylephrine (10 umol/l) (for 0.2 hours) | 56215 | potassium ion (80 mmol/l) (for 0.2 hours) | phenylephrine (10 umol/l) (for 0.2 hours) | | | | | | | |

8 | maximum contractile force per wet weight of aorta | FHH/EurMcwi | male | 1.2175 | g/mg | potassium ion (80 mmol/l) (for 0.2 hours) and phenylephrine (10 umol/l) (for 0.2 hours) | 56221 | potassium ion (80 mmol/l) (for 0.2 hours) | phenylephrine (10 umol/l) (for 0.2 hours) | | | | | | | |

5 | concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50) | FHH/EurMcwi | female | 0.0569 | E-7mole | phenylephrine (1 umol/l) (for 0.2 hours) then sodium nitroprusside (0~3 umol/l) and drug dose time series (for 1 hours) | 56809 | phenylephrine (1 umol/l) (for 0.2 hours) | | sodium nitroprusside (0~3 umol/l) | drug dose time series (for 1 hours) | | | | | |

5 | concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50) | FHH/EurMcwi | male | 0.0908 | E-7mole | phenylephrine (1 umol/l) (for 0.2 hours) then sodium nitroprusside (0~3 umol/l) and drug dose time series (for 1 hours) | 56812 | phenylephrine (1 umol/l) (for 0.2 hours) | | sodium nitroprusside (0~3 umol/l) | drug dose time series (for 1 hours) | | | | | |

6 | concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50) | FHH/EurMcwi | female | 0.0862 | E-7mole | phenylephrine (1 umol/l) (for 0.2 hours) then sodium nitroprusside (0~3 umol/l) and drug dose time series (for 1 hours) | 56693 | phenylephrine (1 umol/l) (for 0.2 hours) | | sodium nitroprusside (0~3 umol/l) | drug dose time series (for 1 hours) | | | | | |

5 | concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50) | FHH/EurMcwi | male | 0.0141 | E-7mole | phenylephrine (1 umol/l) (for 0.2 hours) then sodium nitroprusside (0~3 umol/l) and drug dose time series (for 1 hours) | 56699 | phenylephrine (1 umol/l) (for 0.2 hours) | | sodium nitroprusside (0~3 umol/l) | drug dose time series (for 1 hours) | | | | | |

2 | concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50) | FHH/EurMcwi | male | 0.0263 | E-7mole | phenylephrine (1 umol/l) (for 0.2 hours) then sodium nitroprusside (0~3 umol/l) and drug dose time series (for 1 hours) | 55745 | phenylephrine (1 umol/l) (for 0.2 hours) | | sodium nitroprusside (0~3 umol/l) | drug dose time series (for 1 hours) | | | | | |

6 | concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50) | FHH/EurMcwi | female | 0.2557 | E-7mole | controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) (for 0.2 hours) then sodium nitroprusside (0~3 umol/l) and drug dose time series (for 1 hours) | 56260 | controlled sodium content diet (4 %) (for 21 days) | | phenylephrine (1 umol/l) (for 0.2 hours) | | sodium nitroprusside (0~3 umol/l) | drug dose time series (for 1 hours) | | | |

6 | concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50) | FHH/EurMcwi | male | 0.0259 | E-7mole | controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) (for 0.2 hours) then sodium nitroprusside (0~3 umol/l) and drug dose time series (for 1 hours) | 56266 | controlled sodium content diet (4 %) (for 21 days) | | phenylephrine (1 umol/l) (for 0.2 hours) | | sodium nitroprusside (0~3 umol/l) | drug dose time series (for 1 hours) | | | |

5 | concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50) | FHH/EurMcwi | female | 0.0329 | E-7mole | controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) (for 0.2 hours) then sodium nitroprusside (0~3 umol/l) and drug dose time series (for 1 hours) | 56228 | controlled sodium content diet (4 %) (for 21 days) | | phenylephrine (1 umol/l) (for 0.2 hours) | | sodium nitroprusside (0~3 umol/l) | drug dose time series (for 1 hours) | | | |

11 | concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50) | FHH/EurMcwi | male | 0.1014 | E-7mole | controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) (for 0.2 hours) then sodium nitroprusside (0~3 umol/l) and drug dose time series (for 1 hours) | 56240 | controlled sodium content diet (4 %) (for 21 days) | | phenylephrine (1 umol/l) (for 0.2 hours) | | sodium nitroprusside (0~3 umol/l) | drug dose time series (for 1 hours) | | | |

10 | concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50) | FHH/EurMcwi | female | 1.4528 | E-7mole | phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0~30 umol/l) and drug dose time series (for 1 hours) | 56786 | phenylephrine (1 umol/l) (for 0.2 hours) | | acetylcholine (0~30 umol/l) | drug dose time series (for 1 hours) | | | | | |

5 | concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50) | FHH/EurMcwi | male | 0.6256 | E-7mole | phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0~30 umol/l) and drug dose time series (for 1 hours) | 56792 | phenylephrine (1 umol/l) (for 0.2 hours) | | acetylcholine (0~30 umol/l) | drug dose time series (for 1 hours) | | | | | |

10 | concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50) | FHH/EurMcwi | female | 1.5838 | E-7mole | controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0~30 umol/l) and drug dose time series (for 1 hours) | 56534 | controlled sodium content diet (4 %) (for 21 days) | | phenylephrine (1 umol/l) (for 0.2 hours) | | acetylcholine (0~30 umol/l) | drug dose time series (for 1 hours) | | | |

50 | concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50) | FHH/EurMcwi | male | 1.3813 | E-7mole | controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0~30 umol/l) and drug dose time series (for 1 hours) | 56553 | controlled sodium content diet (4 %) (for 21 days) | | phenylephrine (1 umol/l) (for 0.2 hours) | | acetylcholine (0~30 umol/l) | drug dose time series (for 1 hours) | | | |

6 | concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50) | FHH/EurMcwi | female | 1.197 | E-7mole | controlled sodium content diet (4 %) (for 14 days) then phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0~30 umol/l) and drug dose time series (for 1 hours) | 63029 | controlled sodium content diet (4 %) (for 14 days) | | phenylephrine (1 umol/l) (for 0.2 hours) | | acetylcholine (0~30 umol/l) | drug dose time series (for 1 hours) | | | |

112 | concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50) | FHH/EurMcwi | male | 1.312 | E-7mole | controlled sodium content diet (4 %) (for 14 days) then phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0~30 umol/l) and drug dose time series (for 1 hours) | 63038 | controlled sodium content diet (4 %) (for 14 days) | | phenylephrine (1 umol/l) (for 0.2 hours) | | acetylcholine (0~30 umol/l) | drug dose time series (for 1 hours) | | | |

5 | concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50) | FHH/EurMcwi | female | 0.995 | E-7mole | phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0~30 umol/l) and drug dose time series (for 1 hours) | 57127 | phenylephrine (1 umol/l) (for 0.2 hours) | | acetylcholine (0~30 umol/l) | drug dose time series (for 1 hours) | | | | | |

5 | concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50) | FHH/EurMcwi | male | 1.8032 | E-7mole | phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0~30 umol/l) and drug dose time series (for 1 hours) | 57130 | phenylephrine (1 umol/l) (for 0.2 hours) | | acetylcholine (0~30 umol/l) | drug dose time series (for 1 hours) | | | | | |

8 | concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50) | FHH/EurMcwi | female | 1.3372 | E-7mole | phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0~30 umol/l) and drug dose time series (for 1 hours) | 55908 | phenylephrine (1 umol/l) (for 0.2 hours) | | acetylcholine (0~30 umol/l) | drug dose time series (for 1 hours) | | | | | |

46 | concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50) | FHH/EurMcwi | male | 1.6654 | E-7mole | phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0~30 umol/l) and drug dose time series (for 1 hours) | 55927 | phenylephrine (1 umol/l) (for 0.2 hours) | | acetylcholine (0~30 umol/l) | drug dose time series (for 1 hours) | | | | | |

7 | concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50) | FHH/EurMcwi | female | 0.9222 | E-7mole | controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0~30 umol/l) and drug dose time series (for 1 hours) | 54589 | controlled sodium content diet (4 %) (for 21 days) | | phenylephrine (1 umol/l) (for 0.2 hours) | | acetylcholine (0~30 umol/l) | drug dose time series (for 1 hours) | | | |

7 | concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50) | FHH/EurMcwi | male | 1.3843 | E-7mole | controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0~30 umol/l) and drug dose time series (for 1 hours) | 54595 | controlled sodium content diet (4 %) (for 21 days) | | phenylephrine (1 umol/l) (for 0.2 hours) | | acetylcholine (0~30 umol/l) | drug dose time series (for 1 hours) | | | |

6 | logarithm of the concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (Log EC50) | FHH/EurMcwi | female | -8.1092 | | controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0~300 umol/l) and drug dose time series (for 1.2 hours) | 63097 | controlled sodium content diet (4 %) (for 14 days) | | phenylephrine (0~300 umol/l) | drug dose time series (for 1.2 hours) | | | | | |

119 | logarithm of the concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (Log EC50) | FHH/EurMcwi | male | -8.1504 | | controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0~300 umol/l) and drug dose time series (for 1.2 hours) | 63108 | controlled sodium content diet (4 %) (for 14 days) | | phenylephrine (0~300 umol/l) | drug dose time series (for 1.2 hours) | | | | | |

8 | logarithm of the concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (Log EC50) | FHH/EurMcwi | female | -6.1765 | | controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0~300 umol/l) and drug dose time series (for 1.2 hours) | 55720 | controlled sodium content diet (4 %) (for 21 days) | | phenylephrine (0~300 umol/l) | drug dose time series (for 1.2 hours) | | | | | |

8 | logarithm of the concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (Log EC50) | FHH/EurMcwi | male | -6.2629 | | controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0~300 umol/l) and drug dose time series (for 1.2 hours) | 55726 | controlled sodium content diet (4 %) (for 21 days) | | phenylephrine (0~300 umol/l) | drug dose time series (for 1.2 hours) | | | | | |

10 | logarithm of the concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (Log EC50) | FHH/EurMcwi | female | -7.3723 | | phenylephrine (0~300 umol/l) and drug dose time series (for 1.2 hours) | 55705 | phenylephrine (0~300 umol/l) | drug dose time series (for 1.2 hours) | | | | | | | |

6 | logarithm of the concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (Log EC50) | FHH/EurMcwi | male | -7.4738 | | phenylephrine (0~300 umol/l) and drug dose time series (for 1.2 hours) | 55711 | phenylephrine (0~300 umol/l) | drug dose time series (for 1.2 hours) | | | | | | | |

8 | logarithm of the concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (Log EC50) | FHH/EurMcwi | female | -8.3539 | | phenylephrine (0~300 umol/l) and drug dose time series (for 1.2 hours) | 55289 | phenylephrine (0~300 umol/l) | drug dose time series (for 1.2 hours) | | | | | | | |

50 | logarithm of the concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (Log EC50) | FHH/EurMcwi | male | -7.8613 | | phenylephrine (0~300 umol/l) and drug dose time series (for 1.2 hours) | 55308 | phenylephrine (0~300 umol/l) | drug dose time series (for 1.2 hours) | | | | | | | |

5 | logarithm of the concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (Log EC50) | FHH/EurMcwi | female | -7.3944 | | phenylephrine (0~300 umol/l) and drug dose time series (for 1.2 hours) | 56173 | phenylephrine (0~300 umol/l) | drug dose time series (for 1.2 hours) | | | | | | | |

5 | logarithm of the concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (Log EC50) | FHH/EurMcwi | male | -7.5624 | | phenylephrine (0~300 umol/l) and drug dose time series (for 1.2 hours) | 56176 | phenylephrine (0~300 umol/l) | drug dose time series (for 1.2 hours) | | | | | | | |

10 | logarithm of the concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (Log EC50) | FHH/EurMcwi | female | -7.7571 | | controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0~300 umol/l) and drug dose time series (for 1.2 hours) | 56119 | controlled sodium content diet (4 %) (for 21 days) | | phenylephrine (0~300 umol/l) | drug dose time series (for 1.2 hours) | | | | | |

54 | logarithm of the concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (Log EC50) | FHH/EurMcwi | male | -7.8459 | | controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0~300 umol/l) and drug dose time series (for 1.2 hours) | 56138 | controlled sodium content diet (4 %) (for 21 days) | | phenylephrine (0~300 umol/l) | drug dose time series (for 1.2 hours) | | | | | |

6 | concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50) | FHH/EurMcwi | female | 0.0094 | E-6mole | controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0~300 umol/l) and drug dose time series (for 1.2 hours) | 62774 | controlled sodium content diet (4 %) (for 14 days) | | phenylephrine (0~300 umol/l) | drug dose time series (for 1.2 hours) | | | | | |

119 | concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50) | FHH/EurMcwi | male | 0.0129 | E-6mole | controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0~300 umol/l) and drug dose time series (for 1.2 hours) | 62785 | controlled sodium content diet (4 %) (for 14 days) | | phenylephrine (0~300 umol/l) | drug dose time series (for 1.2 hours) | | | | | |

8 | concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50) | FHH/EurMcwi | female | 0.7388 | E-6mole | controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0~300 umol/l) and drug dose time series (for 1.2 hours) | 56876 | controlled sodium content diet (4 %) (for 21 days) | | phenylephrine (0~300 umol/l) | drug dose time series (for 1.2 hours) | | | | | |

8 | concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50) | FHH/EurMcwi | male | 0.6332 | E-6mole | controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0~300 umol/l) and drug dose time series (for 1.2 hours) | 56882 | controlled sodium content diet (4 %) (for 21 days) | | phenylephrine (0~300 umol/l) | drug dose time series (for 1.2 hours) | | | | | |

5 | concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50) | FHH/EurMcwi | female | 0.0428 | E-6mole | phenylephrine (0~300 umol/l) and drug dose time series (for 1.2 hours) | 55124 | phenylephrine (0~300 umol/l) | drug dose time series (for 1.2 hours) | | | | | | | |

5 | concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50) | FHH/EurMcwi | male | 0.0322 | E-6mole | phenylephrine (0~300 umol/l) and drug dose time series (for 1.2 hours) | 55127 | phenylephrine (0~300 umol/l) | drug dose time series (for 1.2 hours) | | | | | | | |

10 | concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50) | FHH/EurMcwi | female | 0.0523 | E-6mole | phenylephrine (0~300 umol/l) and drug dose time series (for 1.2 hours) | 54987 | phenylephrine (0~300 umol/l) | drug dose time series (for 1.2 hours) | | | | | | | |

6 | concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50) | FHH/EurMcwi | male | 0.0466 | E-6mole | phenylephrine (0~300 umol/l) and drug dose time series (for 1.2 hours) | 54993 | phenylephrine (0~300 umol/l) | drug dose time series (for 1.2 hours) | | | | | | | |

10 | concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50) | FHH/EurMcwi | female | 0.0239 | E-6mole | controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0~300 umol/l) and drug dose time series (for 1.2 hours) | 54920 | controlled sodium content diet (4 %) (for 21 days) | | phenylephrine (0~300 umol/l) | drug dose time series (for 1.2 hours) | | | | | |

54 | concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50) | FHH/EurMcwi | male | 0.0508 | E-6mole | controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0~300 umol/l) and drug dose time series (for 1.2 hours) | 54939 | controlled sodium content diet (4 %) (for 21 days) | | phenylephrine (0~300 umol/l) | drug dose time series (for 1.2 hours) | | | | | |

8 | concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50) | FHH/EurMcwi | female | 0.0079 | E-6mole | phenylephrine (0~300 umol/l) and drug dose time series (for 1.2 hours) | 54688 | phenylephrine (0~300 umol/l) | drug dose time series (for 1.2 hours) | | | | | | | |

50 | concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50) | FHH/EurMcwi | male | 0.0174 | E-6mole | phenylephrine (0~300 umol/l) and drug dose time series (for 1.2 hours) | 54707 | phenylephrine (0~300 umol/l) | drug dose time series (for 1.2 hours) | | | | | | | |

10 | acetylcholine-induced blood vessel dilation expressed as percent of force at maximum constriction | FHH/EurMcwi | female | 78.3 | % | phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0~30 umol/l) and drug dose time series (for 1 hours) | 56841 | phenylephrine (1 umol/l) (for 0.2 hours) | | acetylcholine (0~30 umol/l) | drug dose time series (for 1 hours) | | | | | |

6 | acetylcholine-induced blood vessel dilation expressed as percent of force at maximum constriction | FHH/EurMcwi | male | 88.6667 | % | phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0~30 umol/l) and drug dose time series (for 1 hours) | 56847 | phenylephrine (1 umol/l) (for 0.2 hours) | | acetylcholine (0~30 umol/l) | drug dose time series (for 1 hours) | | | | | |

6 | acetylcholine-induced blood vessel dilation expressed as percent of force at maximum constriction | FHH/EurMcwi | female | 80.3333 | % | controlled sodium content diet (4 %) (for 14 days) then phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0~30 umol/l) and drug dose time series (for 1 hours) | 62629 | controlled sodium content diet (4 %) (for 14 days) | | phenylephrine (1 umol/l) (for 0.2 hours) | | acetylcholine (0~30 umol/l) | drug dose time series (for 1 hours) | | | |

111 | acetylcholine-induced blood vessel dilation expressed as percent of force at maximum constriction | FHH/EurMcwi | male | 65.3423 | % | controlled sodium content diet (4 %) (for 14 days) then phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0~30 umol/l) and drug dose time series (for 1 hours) | 62638 | controlled sodium content diet (4 %) (for 14 days) | | phenylephrine (1 umol/l) (for 0.2 hours) | | acetylcholine (0~30 umol/l) | drug dose time series (for 1 hours) | | | |

5 | acetylcholine-induced blood vessel dilation expressed as percent of force at maximum constriction | FHH/EurMcwi | female | 55.8 | % | phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0~30 umol/l) and drug dose time series (for 1 hours) | 57296 | phenylephrine (1 umol/l) (for 0.2 hours) | | acetylcholine (0~30 umol/l) | drug dose time series (for 1 hours) | | | | | |

5 | acetylcholine-induced blood vessel dilation expressed as percent of force at maximum constriction | FHH/EurMcwi | male | 61.4 | % | phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0~30 umol/l) and drug dose time series (for 1 hours) | 57299 | phenylephrine (1 umol/l) (for 0.2 hours) | | acetylcholine (0~30 umol/l) | drug dose time series (for 1 hours) | | | | | |

8 | acetylcholine-induced blood vessel dilation expressed as percent of force at maximum constriction | FHH/EurMcwi | female | 61.5 | % | phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0~30 umol/l) and drug dose time series (for 1 hours) | 57238 | phenylephrine (1 umol/l) (for 0.2 hours) | | acetylcholine (0~30 umol/l) | drug dose time series (for 1 hours) | | | | | |

47 | acetylcholine-induced blood vessel dilation expressed as percent of force at maximum constriction | FHH/EurMcwi | male | 71.4894 | % | phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0~30 umol/l) and drug dose time series (for 1 hours) | 57257 | phenylephrine (1 umol/l) (for 0.2 hours) | | acetylcholine (0~30 umol/l) | drug dose time series (for 1 hours) | | | | | |

7 | acetylcholine-induced blood vessel dilation expressed as percent of force at maximum constriction | FHH/EurMcwi | female | 84.8571 | % | controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0~30 umol/l) and drug dose time series (for 1 hours) | 55101 | controlled sodium content diet (4 %) (for 21 days) | | phenylephrine (1 umol/l) (for 0.2 hours) | | acetylcholine (0~30 umol/l) | drug dose time series (for 1 hours) | | | |

7 | acetylcholine-induced blood vessel dilation expressed as percent of force at maximum constriction | FHH/EurMcwi | male | 85 | % | controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0~30 umol/l) and drug dose time series (for 1 hours) | 55107 | controlled sodium content diet (4 %) (for 21 days) | | phenylephrine (1 umol/l) (for 0.2 hours) | | acetylcholine (0~30 umol/l) | drug dose time series (for 1 hours) | | | |

9 | acetylcholine-induced blood vessel dilation expressed as percent of force at maximum constriction | FHH/EurMcwi | female | 61.4444 | % | controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0~30 umol/l) and drug dose time series (for 1 hours) | 54794 | controlled sodium content diet (4 %) (for 21 days) | | phenylephrine (1 umol/l) (for 0.2 hours) | | acetylcholine (0~30 umol/l) | drug dose time series (for 1 hours) | | | |

50 | acetylcholine-induced blood vessel dilation expressed as percent of force at maximum constriction | FHH/EurMcwi | male | 71.46 | % | controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0~30 umol/l) and drug dose time series (for 1 hours) | 54813 | controlled sodium content diet (4 %) (for 21 days) | | phenylephrine (1 umol/l) (for 0.2 hours) | | acetylcholine (0~30 umol/l) | drug dose time series (for 1 hours) | | | |

6 | logarithm of the concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50) | FHH/EurMcwi | female | -7.0863 | | controlled sodium content diet (4 %) (for 14 days) then phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0~30 umol/l) and drug dose time series (for 1 hours) | 62852 | controlled sodium content diet (4 %) (for 14 days) | | phenylephrine (1 umol/l) (for 0.2 hours) | | acetylcholine (0~30 umol/l) | drug dose time series (for 1 hours) | | | |

112 | logarithm of the concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50) | FHH/EurMcwi | male | -6.9991 | | controlled sodium content diet (4 %) (for 14 days) then phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0~30 umol/l) and drug dose time series (for 1 hours) | 62861 | controlled sodium content diet (4 %) (for 14 days) | | phenylephrine (1 umol/l) (for 0.2 hours) | | acetylcholine (0~30 umol/l) | drug dose time series (for 1 hours) | | | |

7 | logarithm of the concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50) | FHH/EurMcwi | female | -7.495 | | controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0~30 umol/l) and drug dose time series (for 1 hours) | 57403 | controlled sodium content diet (4 %) (for 21 days) | | phenylephrine (1 umol/l) (for 0.2 hours) | | acetylcholine (0~30 umol/l) | drug dose time series (for 1 hours) | | | |

7 | logarithm of the concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50) | FHH/EurMcwi | male | -7.0874 | | controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0~30 umol/l) and drug dose time series (for 1 hours) | 57409 | controlled sodium content diet (4 %) (for 21 days) | | phenylephrine (1 umol/l) (for 0.2 hours) | | acetylcholine (0~30 umol/l) | drug dose time series (for 1 hours) | | | |

9 | logarithm of the concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50) | FHH/EurMcwi | female | -6.8599 | | controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0~30 umol/l) and drug dose time series (for 1 hours) | 56929 | controlled sodium content diet (4 %) (for 21 days) | | phenylephrine (1 umol/l) (for 0.2 hours) | | acetylcholine (0~30 umol/l) | drug dose time series (for 1 hours) | | | |

50 | logarithm of the concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50) | FHH/EurMcwi | male | -6.9339 | | controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0~30 umol/l) and drug dose time series (for 1 hours) | 56948 | controlled sodium content diet (4 %) (for 21 days) | | phenylephrine (1 umol/l) (for 0.2 hours) | | acetylcholine (0~30 umol/l) | drug dose time series (for 1 hours) | | | |

8 | logarithm of the concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50) | FHH/EurMcwi | female | -6.91 | | phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0~30 umol/l) and drug dose time series (for 1 hours) | 55639 | phenylephrine (1 umol/l) (for 0.2 hours) | | acetylcholine (0~30 umol/l) | drug dose time series (for 1 hours) | | | | | |

47 | logarithm of the concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50) | FHH/EurMcwi | male | -6.8693 | | phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0~30 umol/l) and drug dose time series (for 1 hours) | 55658 | phenylephrine (1 umol/l) (for 0.2 hours) | | acetylcholine (0~30 umol/l) | drug dose time series (for 1 hours) | | | | | |

5 | logarithm of the concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50) | FHH/EurMcwi | female | -7.105 | | phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0~30 umol/l) and drug dose time series (for 1 hours) | 55369 | phenylephrine (1 umol/l) (for 0.2 hours) | | acetylcholine (0~30 umol/l) | drug dose time series (for 1 hours) | | | | | |

5 | logarithm of the concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50) | FHH/EurMcwi | male | -6.7624 | | phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0~30 umol/l) and drug dose time series (for 1 hours) | 55372 | phenylephrine (1 umol/l) (for 0.2 hours) | | acetylcholine (0~30 umol/l) | drug dose time series (for 1 hours) | | | | | |

10 | logarithm of the concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50) | FHH/EurMcwi | female | -7.1519 | | phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0~30 umol/l) and drug dose time series (for 1 hours) | 55020 | phenylephrine (1 umol/l) (for 0.2 hours) | | acetylcholine (0~30 umol/l) | drug dose time series (for 1 hours) | | | | | |

5 | logarithm of the concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50) | FHH/EurMcwi | male | -7.2728 | | phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0~30 umol/l) and drug dose time series (for 1 hours) | 55026 | phenylephrine (1 umol/l) (for 0.2 hours) | | acetylcholine (0~30 umol/l) | drug dose time series (for 1 hours) | | | | | |

3 | hypoxia-induced blood vessel dilation expressed as percent of force at maximum constriction | FHH/EurMcwi | female | 42 | % | phenylephrine (1 umol/l) then controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) then controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) then controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours) then controlled oxygen content physiological salt solution perfusate (0 %) (for 0.3 hours) | 56728 | phenylephrine (1 umol/l) | | controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) | | controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) | | controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours) | controlled oxygen content physiological salt solution perfusate (0 %) (for 0.3 hours) | |

5 | hypoxia-induced blood vessel dilation expressed as percent of force at maximum constriction | FHH/EurMcwi | male | 42 | % | phenylephrine (1 umol/l) then controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) then controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) then controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours) then controlled oxygen content physiological salt solution perfusate (0 %) (for 0.3 hours) | 56731 | phenylephrine (1 umol/l) | | controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) | | controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) | | controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours) | controlled oxygen content physiological salt solution perfusate (0 %) (for 0.3 hours) | |

9 | hypoxia-induced blood vessel dilation expressed as percent of force at maximum constriction | FHH/EurMcwi | female | 41 | % | controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) then controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) then controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) then controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours) | 56715 | controlled sodium content diet (4 %) (for 21 days) | | phenylephrine (1 umol/l) | | controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) | | controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) | controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours) | |

10 | hypoxia-induced blood vessel dilation expressed as percent of force at maximum constriction | FHH/EurMcwi | male | 46.3 | % | controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) then controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) then controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) then controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours) | 56721 | controlled sodium content diet (4 %) (for 21 days) | | phenylephrine (1 umol/l) | | controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) | | controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) | controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours) | |

3 | hypoxia-induced blood vessel dilation expressed as percent of force at maximum constriction | FHH/EurMcwi | male | 55 | % | phenylephrine (1 umol/l) then controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) then controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) then controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours) then controlled oxygen content physiological salt solution perfusate (0 %) (for 0.3 hours) | 57178 | phenylephrine (1 umol/l) | | controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) | | controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) | | controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours) | controlled oxygen content physiological salt solution perfusate (0 %) (for 0.3 hours) | |

5 | hypoxia-induced blood vessel dilation expressed as percent of force at maximum constriction | FHH/EurMcwi | female | 56 | % | controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) then controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) then controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) then controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours) then controlled oxygen content physiological salt solution perfusate (0 %) (for 0.3 hours) | 57134 | controlled sodium content diet (4 %) (for 21 days) | | phenylephrine (1 umol/l) | | controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) | | controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) | controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours) | controlled oxygen content physiological salt solution perfusate (0 %) (for 0.3 hours) |

9 | hypoxia-induced blood vessel dilation expressed as percent of force at maximum constriction | FHH/EurMcwi | male | 40 | % | controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) then controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) then controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) then controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours) then controlled oxygen content physiological salt solution perfusate (0 %) (for 0.3 hours) | 57146 | controlled sodium content diet (4 %) (for 21 days) | | phenylephrine (1 umol/l) | | controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) | | controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) | controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours) | controlled oxygen content physiological salt solution perfusate (0 %) (for 0.3 hours) |

11 | hypoxia-induced blood vessel dilation expressed as percent of force at maximum constriction | FHH/EurMcwi | female | 49.1818 | % | phenylephrine (1 umol/l) then controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) then controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) then controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours) | 55356 | phenylephrine (1 umol/l) | | controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) | | controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) | | controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours) | | |

6 | hypoxia-induced blood vessel dilation expressed as percent of force at maximum constriction | FHH/EurMcwi | male | 39.8333 | % | phenylephrine (1 umol/l) then controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) then controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) then controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours) | 55362 | phenylephrine (1 umol/l) | | controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) | | controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) | | controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours) | | |

3 | hypoxia-induced blood vessel dilation expressed as percent of force at maximum constriction | FHH/EurMcwi | male | 32.3333 | % | phenylephrine (1 umol/l) then controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) then controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) | 55143 | phenylephrine (1 umol/l) | | controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) | | controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) | | | | |

5 | hypoxia-induced blood vessel dilation expressed as percent of force at maximum constriction | FHH/EurMcwi | female | 14.4 | % | controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) then controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) then controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) | 55071 | controlled sodium content diet (4 %) (for 21 days) | | phenylephrine (1 umol/l) | | controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) | | controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) | | |

9 | hypoxia-induced blood vessel dilation expressed as percent of force at maximum constriction | FHH/EurMcwi | male | 17 | % | controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) then controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) then controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) | 55083 | controlled sodium content diet (4 %) (for 21 days) | | phenylephrine (1 umol/l) | | controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) | | controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) | | |

3 | hypoxia-induced blood vessel dilation expressed as percent of force at maximum constriction | FHH/EurMcwi | male | 36 | % | phenylephrine (1 umol/l) then controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) then controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) then controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours) | 55055 | phenylephrine (1 umol/l) | | controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) | | controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) | | controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours) | | |

11 | hypoxia-induced blood vessel dilation expressed as percent of force at maximum constriction | FHH/EurMcwi | female | 38.7273 | % | phenylephrine (1 umol/l) then controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) then controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) | 54975 | phenylephrine (1 umol/l) | | controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) | | controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) | | | | |

6 | hypoxia-induced blood vessel dilation expressed as percent of force at maximum constriction | FHH/EurMcwi | male | 33.1667 | % | phenylephrine (1 umol/l) then controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) then controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) | 54981 | phenylephrine (1 umol/l) | | controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) | | controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) | | | | |

9 | hypoxia-induced blood vessel dilation expressed as percent of force at maximum constriction | FHH/EurMcwi | female | 26.5556 | % | controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) then controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) then controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) | 54849 | controlled sodium content diet (4 %) (for 21 days) | | phenylephrine (1 umol/l) | | controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) | | controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) | | |

10 | hypoxia-induced blood vessel dilation expressed as percent of force at maximum constriction | FHH/EurMcwi | male | 33.6 | % | controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) then controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) then controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) | 54855 | controlled sodium content diet (4 %) (for 21 days) | | phenylephrine (1 umol/l) | | controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) | | controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) | | |

3 | hypoxia-induced blood vessel dilation expressed as percent of force at maximum constriction | FHH/EurMcwi | female | 19.6667 | % | phenylephrine (1 umol/l) then controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) then controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) then controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours) | 55989 | phenylephrine (1 umol/l) | | controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) | | controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) | | controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours) | | |

5 | hypoxia-induced blood vessel dilation expressed as percent of force at maximum constriction | FHH/EurMcwi | male | 24.6 | % | phenylephrine (1 umol/l) then controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) then controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) then controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours) | 55992 | phenylephrine (1 umol/l) | | controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) | | controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) | | controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours) | | |

9 | hypoxia-induced blood vessel dilation expressed as percent of force at maximum constriction | FHH/EurMcwi | female | 75.5556 | % | controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) then controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) then controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) then controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours) then controlled oxygen content physiological salt solution perfusate (0 %) (for 0.3 hours) | 56439 | controlled sodium content diet (4 %) (for 21 days) | | phenylephrine (1 umol/l) | | controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) | | controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) | controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours) | controlled oxygen content physiological salt solution perfusate (0 %) (for 0.3 hours) |

10 | hypoxia-induced blood vessel dilation expressed as percent of force at maximum constriction | FHH/EurMcwi | male | 87.3 | % | controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) then controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) then controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) then controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours) then controlled oxygen content physiological salt solution perfusate (0 %) (for 0.3 hours) | 56445 | controlled sodium content diet (4 %) (for 21 days) | | phenylephrine (1 umol/l) | | controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) | | controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) | controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours) | controlled oxygen content physiological salt solution perfusate (0 %) (for 0.3 hours) |

11 | hypoxia-induced blood vessel dilation expressed as percent of force at maximum constriction | FHH/EurMcwi | female | 64.0909 | % | phenylephrine (1 umol/l) then controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) then controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) then controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours) then controlled oxygen content physiological salt solution perfusate (0 %) (for 0.3 hours) | 56333 | phenylephrine (1 umol/l) | | controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) | | controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) | | controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours) | controlled oxygen content physiological salt solution perfusate (0 %) (for 0.3 hours) | |

6 | hypoxia-induced blood vessel dilation expressed as percent of force at maximum constriction | FHH/EurMcwi | male | 62.1667 | % | phenylephrine (1 umol/l) then controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) then controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) then controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours) then controlled oxygen content physiological salt solution perfusate (0 %) (for 0.3 hours) | 56339 | phenylephrine (1 umol/l) | | controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) | | controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) | | controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours) | controlled oxygen content physiological salt solution perfusate (0 %) (for 0.3 hours) | |

5 | hypoxia-induced blood vessel dilation expressed as percent of force at maximum constriction | FHH/EurMcwi | female | 32.2 | % | controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) then controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) then controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) then controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours) | 56271 | controlled sodium content diet (4 %) (for 21 days) | | phenylephrine (1 umol/l) | | controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) | | controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) | controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours) | |

9 | hypoxia-induced blood vessel dilation expressed as percent of force at maximum constriction | FHH/EurMcwi | male | 26.1111 | % | controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) then controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) then controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) then controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours) | 56283 | controlled sodium content diet (4 %) (for 21 days) | | phenylephrine (1 umol/l) | | controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) | | controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) | controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours) | |

3 | hypoxia-induced blood vessel dilation expressed as percent of force at maximum constriction | FHH/EurMcwi | female | 11 | % | phenylephrine (1 umol/l) then controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) then controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) | 56205 | phenylephrine (1 umol/l) | | controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) | | controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) | | | | |

5 | hypoxia-induced blood vessel dilation expressed as percent of force at maximum constriction | FHH/EurMcwi | male | 14.6 | % | phenylephrine (1 umol/l) then controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) then controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) | 56208 | phenylephrine (1 umol/l) | | controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) | | controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) | | | | |

2 | sodium nitroprusside-induced blood vessel dilation expressed as percent of force at maximum constriction | FHH/EurMcwi | male | 100 | % | phenylephrine (1 umol/l) (for 0.2 hours) then sodium nitroprusside (0~3 umol/l) and drug dose time series (for 1 hours) | 56475 | phenylephrine (1 umol/l) (for 0.2 hours) | | sodium nitroprusside (0~3 umol/l) | drug dose time series (for 1 hours) | | | | | |

8 | sodium nitroprusside-induced blood vessel dilation expressed as percent of force at maximum constriction | FHH/EurMcwi | female | 99.375 | % | phenylephrine (1 umol/l) (for 0.2 hours) then sodium nitroprusside (0~3 umol/l) and drug dose time series (for 1 hours) | 55965 | phenylephrine (1 umol/l) (for 0.2 hours) | | sodium nitroprusside (0~3 umol/l) | drug dose time series (for 1 hours) | | | | | |

5 | sodium nitroprusside-induced blood vessel dilation expressed as percent of force at maximum constriction | FHH/EurMcwi | male | 99.6 | % | phenylephrine (1 umol/l) (for 0.2 hours) then sodium nitroprusside (0~3 umol/l) and drug dose time series (for 1 hours) | 55971 | phenylephrine (1 umol/l) (for 0.2 hours) | | sodium nitroprusside (0~3 umol/l) | drug dose time series (for 1 hours) | | | | | |

5 | sodium nitroprusside-induced blood vessel dilation expressed as percent of force at maximum constriction | FHH/EurMcwi | female | 99.8 | % | phenylephrine (1 umol/l) (for 0.2 hours) then sodium nitroprusside (0~3 umol/l) and drug dose time series (for 1 hours) | 55376 | phenylephrine (1 umol/l) (for 0.2 hours) | | sodium nitroprusside (0~3 umol/l) | drug dose time series (for 1 hours) | | | | | |

5 | sodium nitroprusside-induced blood vessel dilation expressed as percent of force at maximum constriction | FHH/EurMcwi | male | 98.6 | % | phenylephrine (1 umol/l) (for 0.2 hours) then sodium nitroprusside (0~3 umol/l) and drug dose time series (for 1 hours) | 55379 | phenylephrine (1 umol/l) (for 0.2 hours) | | sodium nitroprusside (0~3 umol/l) | drug dose time series (for 1 hours) | | | | | |

5 | sodium nitroprusside-induced blood vessel dilation expressed as percent of force at maximum constriction | FHH/EurMcwi | female | 97.6 | % | controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) (for 0.2 hours) then sodium nitroprusside (0~3 umol/l) and drug dose time series (for 1 hours) | 56303 | controlled sodium content diet (4 %) (for 21 days) | | phenylephrine (1 umol/l) (for 0.2 hours) | | sodium nitroprusside (0~3 umol/l) | drug dose time series (for 1 hours) | | | |

11 | sodium nitroprusside-induced blood vessel dilation expressed as percent of force at maximum constriction | FHH/EurMcwi | male | 95 | % | controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) (for 0.2 hours) then sodium nitroprusside (0~3 umol/l) and drug dose time series (for 1 hours) | 56315 | controlled sodium content diet (4 %) (for 21 days) | | phenylephrine (1 umol/l) (for 0.2 hours) | | sodium nitroprusside (0~3 umol/l) | drug dose time series (for 1 hours) | | | |

8 | sodium nitroprusside-induced blood vessel dilation expressed as percent of force at maximum constriction | FHH/EurMcwi | female | 99 | % | controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) (for 0.2 hours) then sodium nitroprusside (0~3 umol/l) and drug dose time series (for 1 hours) | 56194 | controlled sodium content diet (4 %) (for 21 days) | | phenylephrine (1 umol/l) (for 0.2 hours) | | sodium nitroprusside (0~3 umol/l) | drug dose time series (for 1 hours) | | | |

10 | sodium nitroprusside-induced blood vessel dilation expressed as percent of force at maximum constriction | FHH/EurMcwi | male | 100 | % | controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) (for 0.2 hours) then sodium nitroprusside (0~3 umol/l) and drug dose time series (for 1 hours) | 56200 | controlled sodium content diet (4 %) (for 21 days) | | phenylephrine (1 umol/l) (for 0.2 hours) | | sodium nitroprusside (0~3 umol/l) | drug dose time series (for 1 hours) | | | |